PTC Therapeutics (PTCT) director exercises stock option, now holds 155,266 shares

Rhea-AI Filing Summary

PTC Therapeutics director reports stock option exercise and share acquisition. A board member exercised a stock option on 12/16/2025 to acquire 24,000 shares of PTC Therapeutics common stock at an exercise price of $30.86 per share. The transaction is coded "M," indicating an option exercise. Following this transaction, the director beneficially owns 155,266 shares of common stock held directly. The exercised option covered 24,000 shares, was noted as currently exercisable, and carries an expiration date of 01/03/2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHMERTZLER MICHAEL

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		M		24,000	A	$30.86	155,266	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.86	12/16/2025		M			24,000	(1)	01/03/2026	Common Stock	24,000	$0	0	D

Explanation of Responses:

1. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report in this Form 4?

A director of PTC Therapeutics, Inc. reported exercising a stock option on 12/16/2025 to acquire 24,000 shares of common stock at an exercise price of $30.86 per share.

How many PTC Therapeutics (PTCT) shares does the reporting person own after the transaction?

After the reported option exercise, the director beneficially owns 155,266 shares of PTC Therapeutics common stock in direct ownership.

What does the transaction code "M" mean in the PTC Therapeutics (PTCT) Form 4?

The transaction code "M" indicates the exercise or conversion of a derivative security, in this case a stock option (right to buy) that resulted in acquiring common stock.

What were the key terms of the stock option exercised at PTC Therapeutics (PTCT)?

The derivative security was a stock option (right to buy) with an exercise price of $30.86 per share, covering 24,000 underlying shares of PTC Therapeutics common stock, with an expiration date of 01/03/2026.

Is the stock option in the PTC Therapeutics (PTCT) Form 4 currently exercisable?

Yes. The explanation of responses notes that the stock option is currently exercisable, and it was exercised on 12/16/2025 for 24,000 shares.

What is the relationship of the reporting person to PTC Therapeutics (PTCT)?

The reporting person is identified as a Director of PTC Therapeutics, Inc., and the Form 4 is filed for one reporting person only.